HX GROUP(SH:900917)2022-04-18 16:00Financial Performance - In 2021, the company achieved a total revenue of CNY 1,511,255,284.73, representing a 62.03% increase compared to CNY 932,727,985.27 in 2020[24]. - The net profit attributable to shareholders was CNY 132,091,780.53, which is a 10.64% increase from CNY 119,391,753.57 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 103,858,333.22, reflecting a 14.69% increase from CNY 90,558,477.79 in 2020[24]. - The cash flow from operating activities increased by 79.31% to CNY 219,647,104.26, up from CNY 122,499,034.51 in 2020[24]. - The company achieved an operating revenue of 1.511 billion yuan in 2021, representing a year-on-year growth of 62.03%[33]. - The net profit for 2021 was 132 million yuan, an increase of 10.64% compared to the previous year[33]. - The weighted average return on equity rose to 3.12%, up from 2.98% in the previous year[28]. - The basic earnings per share increased to 0.1094 yuan, marking a growth of 10.62% year-on-year[28]. Segment Performance - The pharmaceutical segment generated revenue of 872.99 million yuan, a year-on-year increase of 36.35%[34]. - The revenue from the Gannan Haixin segment reached 595.90 million yuan, growing by 81.72% year-on-year[34]. - The property segment achieved rental income of 71.62 million yuan, reflecting an 18.24% increase from the previous year[35]. - The textile segment accelerated its adjustment, achieving revenue of 204.7 million yuan, a year-on-year decrease of 11.54%, with a consolidated net loss of 3.87 million yuan, improving by 32.44 million yuan year-on-year[36]. - The pharmaceutical manufacturing and sales segment generated a consolidated revenue of 872.99 million RMB, up 36.35% year-on-year, with a net profit of 14.13 million RMB[48]. - The property management segment achieved rental income of 71.62 million RMB, a growth of 18.24% year-on-year, with a net profit of 40.48 million RMB[48]. Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 5,325,619,470.52, a decrease of 5.32% from CNY 5,625,066,071.47 at the end of 2020[24]. - The company's net assets attributable to shareholders were CNY 4,128,288,109.68, showing a slight decrease of 1.45% from CNY 4,189,071,328.66 in 2020[24]. - The company had a total asset value of 5.326 billion RMB at the end of 2021, a decrease of 5.32% year-on-year, primarily due to a decline in the market value of Changjiang Securities[48]. - The company holds overseas assets valued at RMB 92.91 million, which constitutes 1.74% of total assets[70]. Cash Flow and Investments - The cash flow from investment income increased by 30.34% to ¥122,034,892.62, reflecting higher dividends received compared to the previous year[66]. - The company's investment activities resulted in a net cash outflow of 64.16 million RMB, while financing activities saw a net cash outflow of 231.25 million RMB, a significant increase of 317.58% year-on-year[49]. - The company achieved a revenue of 6.74 million yuan from financial investments, including activities related to Jiangsu Securities stocks and new stock subscriptions[40]. - The company has significant investments in structured deposits, with a total initial investment of RMB 240.50 million and a year-end book value of RMB 240.50 million, resulting in a report period profit of RMB 5.58 million[73]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, and operates under established rules to ensure effective governance[97]. - The supervisory board is composed of 2 supervisors and 1 employee supervisor, adhering to legal requirements and effectively overseeing financial compliance[98]. - The company has established a performance evaluation and incentive mechanism linking senior management compensation to company and individual performance[99]. - The company has implemented an information disclosure management system to ensure timely and accurate information dissemination to all shareholders[100]. - The company has established four specialized committees under the board to enhance decision-making efficiency and governance[97]. Risk Management - The company has outlined potential risks in its future development strategies, which investors should be aware of[11]. - The company faces market risks due to intense competition in its pharmaceutical and textile sectors, which could significantly impact performance[88]. - Regulatory risks from stricter environmental policies and changes in healthcare regulations may affect the company's operations in the pharmaceutical and textile sectors[89]. - The company has a structured approach to risk management and compliance, with key personnel holding multiple roles in financial and asset management sectors[115]. Environmental Compliance - The company has successfully maintained ammonia emissions below 4.9 kg/h, adhering to the standards set by GB14554-93[146]. - The concentration of particulate matter from the exhaust is controlled to be less than 120 mg/Nm3, ensuring compliance with air pollution standards[146]. - The wastewater treatment process has a biochemical oxygen demand (BOD) limit of ≤500 mg/L, which is consistently met[146]. - The company reported that the concentration of sulfur dioxide emissions from boiler exhaust is maintained below 300 mg/Nm3, complying with GB13271-2014 standards[145]. - The company has reported no exceedances in the emission limits for all monitored pollutants, demonstrating effective environmental management practices[146]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 63,932, an increase from 63,644 in the previous month[178]. - The largest shareholder, Shenzhen Ningrui Investment Management, holds 141,528,801 shares, representing 11.73% of the total shares[180]. - The second-largest shareholder, Shanghai Songjiang Dongjing Industrial Company, holds 82,082,000 shares, accounting for 6.80%[180]. - The company has not reported any changes in its total share capital or share structure during the reporting period[176]. Strategic Focus - The company plans to continue expanding its market presence and enhancing product quality in response to changing economic conditions and consumer demands[33]. - The company is focusing on strategic planning for the "14th Five-Year Plan," emphasizing revitalizing existing assets and strengthening core businesses, particularly in the pharmaceutical and property sectors[41]. - The company aims to implement a "large property and asset management" model, transitioning from basic property leasing to comprehensive property services and asset management[84]. - The strategic focus includes leveraging new emerging industries and aligning with national policies to support sustainable development and transformation[83].